Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 16 articles: HTML format

Single Articles

March 2025
1. YOKOTA H, Sato K, Sakamoto S, Okuda Y, et al
   Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer.
   Cancer Chemother Pharmacol. 2025;95:49.
   PubMed     Abstract available
   
   
   January 2025
2. FUNAISHI K, Yamaguchi K, Tanahashi H, Kurose K, et al
   HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC.
   Cancer Chemother Pharmacol. 2025;95:28.
   PubMed     Abstract available
   
   
   
3. CHENG CY, Chuang WC, Lin CP, Li CH, et al
   Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study.
   Cancer Chemother Pharmacol. 2025;95:20.
   PubMed     Abstract available
   
   
   December 2024
4. GEZELIUS E, Planck M, Hazem B, Nagpal S, et al
   Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report.
   Cancer Chemother Pharmacol. 2024;95:6.
   PubMed     Abstract available
   
   
   
5. DE ROUW N, Beunders R, Hartmann O, Schulte J, et al
   A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed.
   Cancer Chemother Pharmacol. 2024;94:799-806.
   PubMed     Abstract available
   
   
   September 2024
6. LIN L, van der Noort V, Steeghs N, Ruiter G, et al
   A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinib.
   Cancer Chemother Pharmacol. 2024;94:453-459.
   PubMed     Abstract available
   
   
   July 2024
7. YAMAMOTO N, Koyama T, Sato J, Yoshida T, et al
   Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
   Cancer Chemother Pharmacol. 2024;94:109-115.
   PubMed     Abstract available
   
   
   April 2024
8. XU X, Liu Y, Gong Q, Ma L, et al
   PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.
   Cancer Chemother Pharmacol. 2024 Apr 12. doi: 10.1007/s00280-024-04668.
   PubMed     Abstract available
   
   
   
9. URYU K, Imamura Y, Shimoyama R, Mase T, et al
   Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.
   Cancer Chemother Pharmacol. 2024 Apr 8. doi: 10.1007/s00280-024-04666.
   PubMed     Abstract available
   
   
   March 2024
10. HUO H, Feng Y, Tang Q
    Correction to: Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.
    Cancer Chemother Pharmacol. 2024 Mar 26. doi: 10.1007/s00280-024-04646.
    PubMed    
    
    
    February 2024
11. MA X, Sun Z, Chen H, Cao L, et al
    18beta-glycyrrhetinic acid suppresses Lewis lung cancer growth through protecting immune cells from ferroptosis.
    Cancer Chemother Pharmacol. 2024 Feb 21. doi: 10.1007/s00280-024-04639.
    PubMed     Abstract available
    
    
    January 2024
12. YU F, Huo H, Tang Q
    Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy.
    Cancer Chemother Pharmacol. 2024 Jan 4. doi: 10.1007/s00280-023-04630.
    PubMed     Abstract available
    
    
    
13. LI MY, Zhang J, Lu X, Zhou D, et al
    Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells.
    Cancer Chemother Pharmacol. 2024;93:41-54.
    PubMed     Abstract available
    
    
    November 2023
14. WANG X, Gu S, Wen J, Zhang L, et al
    Association between chemotherapy-induced myelosuppression and curative efficacy of 2-cycle chemotherapy in small cell lung cancer.
    Cancer Chemother Pharmacol. 2023 Nov 5. doi: 10.1007/s00280-023-04608.
    PubMed     Abstract available
    
    
    
15. MA Y, Chen Q, Zhang Y, Xue J, et al
    Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
    Cancer Chemother Pharmacol. 2023;92:411-418.
    PubMed     Abstract available
    
    
    September 2023
16. CHENG M, Yang F, Yang Y, Gao X, et al
    Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer.
    Cancer Chemother Pharmacol. 2023 Sep 23. doi: 10.1007/s00280-023-04590.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.